ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Bid For US Approval Of New Use For Humira Is Delayed

By Peter Loftus Of DOW JONES NEWSWIRES Abbott Laboratories (ABT) has encountered a delay in its bid for U.S. regulatory approval to expand the uses of its blockbuster anti-inflammatory drug Humira to include treatment of the bowel disease ulcerative colitis. Abbott received a "complete response letter" from the U.S. Food and Drug Administration in late 2011 regarding Abbott's application to market Humira for colitis, spokeswoman Elizabeth Hoff said Monday. The FDA sends such letters when a drug application isn't yet ready for approval. The Abbott Park, Ill., company has provided additional information and continues to have a dialogue with the FDA, Hoff said. Abbott expects an agency decision by the end of this year, she said. She declined to provide contents of the complete response letter. Abbott filed for regulatory approval of Humira to treat ulcerative colitis in the U.S. and Europe in early 2011. The European Commission approved the new use in April. The regulatory applications were based on clinical data showing that Humira improved rates of disease remission versus a placebo in people with colitis, an inflammatory bowel disease that causes pain, diarrhea and other symptoms. Humira is currently approved in the U.S. to treat rheumatoid arthritis and several other inflammatory conditions. Abbott recorded $7.9 billion in Humira sales for 2011. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Abbott Labs (ABT)
DateTimeHeadline
04/16/201413:42:24U.S. Hot Stocks: Hot Stocks to Watch
04/16/201413:41:44Abbott Labs Profit Falls 31%
04/16/201403:23:12Abbott Laboratories Statement re Proxy Materials
04/16/201403:23:12Abbott Laboratories Statement re Current Reports
04/13/201408:46:33MARKET SNAPSHOT: Google, Intel, IBM Outlooks To Trump Earnings...
02/14/201418:20:25Loeb's Third Point Took New Stakes in T-Mobile, Hertz, BlackBerry...
01/22/201413:24:11Abbott Labs Reports 44% Profit Decline -- Update
01/19/201408:17:14MARKET SNAPSHOT: 'Sloppy' Market Turns To Consumer, Tech Earnings
11/18/201308:56:09AbbVie's Treatment for Hepatitis C Shows Positive Results in...
11/15/201309:01:33HBK Investments LP 3Q 13F: Holdings As Of Sep 30
11/15/201309:01:33HBK Investments LP 3Q 13F: Holdings As Of Sep 30 -2-
11/15/201308:55:36Highbridge Capital Management 3Q 13F: Holdings As -2-
11/15/201308:55:35Highbridge Capital Management 3Q 13F: Holdings As Of Sep 30
11/15/201308:53:17D. E. Shaw & Co. LP 3Q 13F: Holdings As Of Sep 30
11/15/201308:53:17D. E. Shaw & Co. LP 3Q 13F: Holdings As Of Sep 30 -2-
11/15/201308:22:25Janus Capital Management 3Q 13F: Largest Purchases -2-
11/15/201308:22:24Janus Capital Management 3Q 13F: Holdings As Of -2-
11/15/201308:22:24Janus Capital Management 3Q 13F: Largest Purchases
11/15/201308:22:23Janus Capital Management 3Q 13F: Holdings As Of Sep 30
11/15/201307:59:25Soros Fund Management 3Q 13F: Largest Purchases

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad